Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Keytruda after weekly paclitaxel in recurrent ovarian, fallopian tube or primary peritoneal cancer
2017-003792-63Phase 2Unknown
- Sponsor
- University College London
- Start
- Sep 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer (OC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University College London. Primary endpoint: Progression-free survival rate at 6 months from start of maintenance pembrolizumab. Status: unknown.
02
Drugs
03
Conditions
ovarian cancer (OC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-003792-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003792-63.